Merck & Co. (NYSE:MRK) had its price objective raised by analysts at Bank of America from $68.00 to $70.00 in a report released on Tuesday. The brokerage currently has a “buy” rating on the stock. Bank of America’s target price indicates a potential upside of 18.81% from the company’s current price.
MRK has been the subject of a number of other reports. Jefferies Group set a $55.00 price objective on shares of Merck & Co. and gave the stock a “hold” rating in a report on Friday, March 23rd. ValuEngine lowered shares of Merck & Co. from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. DZ Bank upgraded shares of Merck & Co. from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. Morgan Stanley boosted their price objective on shares of Merck & Co. from $60.00 to $63.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 7th. Finally, Credit Suisse Group decreased their price objective on shares of Merck & Co. from $67.00 to $66.00 and set an “outperform” rating for the company in a report on Monday, February 5th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company’s stock. Merck & Co. has an average rating of “Buy” and an average price target of $66.83.
Shares of NYSE MRK opened at $58.92 on Tuesday. Merck & Co. has a twelve month low of $52.83 and a twelve month high of $66.41. The company has a market capitalization of $159,803.17, a P/E ratio of 14.89, a PEG ratio of 2.48 and a beta of 0.78. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62.
Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. The company had revenue of $10.43 billion during the quarter, compared to analyst estimates of $10.48 billion. During the same period in the previous year, the business earned $0.89 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. sell-side analysts expect that Merck & Co. will post 4.16 earnings per share for the current fiscal year.
In other news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $53.57, for a total value of $267,850.00. Following the completion of the sale, the director now directly owns 5,100 shares in the company, valued at approximately $273,207. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the company’s stock in a transaction on Monday, April 16th. The stock was sold at an average price of $58.00, for a total value of $1,392,000.00. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the company. Honeywell International Inc. increased its stake in shares of Merck & Co. by 18.8% in the 3rd quarter. Honeywell International Inc. now owns 633,700 shares of the company’s stock worth $40,576,000 after purchasing an additional 100,500 shares in the last quarter. D.A. Davidson & CO. increased its stake in shares of Merck & Co. by 18.3% in the 3rd quarter. D.A. Davidson & CO. now owns 524,481 shares of the company’s stock worth $33,582,000 after purchasing an additional 81,290 shares in the last quarter. Train Babcock Advisors LLC increased its stake in shares of Merck & Co. by 19.8% in the 4th quarter. Train Babcock Advisors LLC now owns 10,810 shares of the company’s stock worth $609,000 after purchasing an additional 1,785 shares in the last quarter. Ascension Asset Management LLC purchased a new stake in shares of Merck & Co. in the 4th quarter worth $644,000. Finally, Mork Capital Management LLC purchased a new stake in shares of Merck & Co. in the 4th quarter worth $990,000. Hedge funds and other institutional investors own 74.60% of the company’s stock.
WARNING: “Bank of America Increases Merck & Co. (MRK) Price Target to $70.00” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2018/04/19/bank-of-america-increases-merck-co-mrk-price-target-to-70-00.html.
About Merck & Co.
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.